Core Points - The Department of Health and Human Services (HHS) and the White House have shared a 2017 tweet from Tylenol, reigniting discussions about a potential link between the drug and autism in children [2][4] - Kenvue, the parent company of Tylenol, stated that the tweet was taken out of context and emphasized that acetaminophen is considered the safest pain reliever during pregnancy [3][4] - A recent study from the Icahn School of Medicine at Mount Sinai supports evidence of a link between prenatal acetaminophen use and increased risks of autism and ADHD, analyzing data from over 100,000 participants [5] Company Impact - Following the renewed controversy, Kenvue's stock experienced a significant decline, dropping over 11% in the past five days due to fears of potential litigation stemming from the discussions [6] - HHS Secretary Robert F. Kennedy Jr. announced plans for a nationwide campaign advising clinicians to prescribe the lowest effective dose of acetaminophen during pregnancy [7] - Kenvue's stock is currently showing a weak price trend across short, medium, and long-term periods, with a poor momentum ranking of 9.67% [7]